RT Journal Article
SR Electronic
T1 Phase II Study of Docetaxel Plus Cisplatin as a Second-line Combined Therapy in Patients with Advanced Gastric Carcinoma
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 2973
OP 2977
VO 25
IS 4
A1 KUNISAKI, CHIKARA
A1 IMADA, TOSHIO
A1 YAMADA, ROPPEI
A1 HATORI, SHINSUKE
A1 ONO, HIDETAKA
A1 OTSUKA, YUICHI
A1 MATSUDA, GORO
A1 NOMURA, MASATO
A1 AKIYAMA, HIROTOSHI
A1 KUBO, AKIRA
A1 SHIMADA, HIROSHI
YR 2005
UL http://ar.iiarjournals.org/content/25/4/2973.abstract
AB Background: We conducted a pilot phase II study to evaluate the efficacy and safety of docetaxel and cisplatin as a combination second-line therapy for advanced gastric cancer. Patients and Methods: Between 2000 and 2003, 30 patients were enrolled into this study. Chemotherapy consisted of 60 mg/m2 of docetaxel followed by 60 mg/m2 of cisplatin. This regimen was repeated at least three times at 3-week intervals. Results: The overall response rate was 26.7%. The median time to disease progression was 4.5 months. The median survival time was 13 months from the start of the first-line therapy and 6 months from the second-line therapy. With respect to toxicity, the major adverse effect was leukopenia, which reached grades 3-4 in 26.7%. Non-hematological toxicities were usually moderate, and no deaths were attributable to the adverse effects of the drugs. Conclusion: This combination therapy was effective as a second-line treatment for advanced gastric cancer with acceptable toxic side-effects. Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved